Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1141-1160 of 2,251 trials

Colorectal Polyp Removal: Anticoagulants and Antiplatelets Study

We are investigating whether continuing blood-thinning medications during polypectomy for small colorectal polyps affects bleeding risks. This study will also assess heart-related risks when these medications are stopped.

Healthy Participants Undergoing Colonoscopy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyHematology

Blood Cancer: Long-term Study of Zanubrutinib

We are evaluating the long-term safety and effectiveness of Zanubrutinib in patients with B-cell malignancies. This study is for those who have previously participated in a related trial.

B-cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Non-Small Cell Lung Cancer: Sotorasib Treatment Study

We are studying the effects of Sotorasib in patients with non-operable non-small cell lung cancer who have a KRAS mutation. The goal is to see if this treatment improves survival and response rates compared to standard options.

Stage III Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Anti-CD19 CAR T-Cell Therapy for Autoimmune Diseases

We are studying a new treatment for people with active B-driven autoimmune diseases like lupus and scleroderma. The trial aims to evaluate its safety and initial effectiveness in managing these conditions.

Refractory Systemic Autoimmune Diseases3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Myelofibrosis: Selinexor Treatment Study

We are studying the effects of selinexor in patients with myelofibrosis who haven't been treated with JAK inhibitors. The goal is to see if it helps improve symptoms and overall health.

MyelofibrosisModerate ThrombocytopeniaEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Advanced Non-Small Cell Lung Cancer: BAY 2927088 Study

We are investigating how well BAY 2927088 works and its safety compared to standard treatment for patients with advanced non-small cell lung cancer with HER2 mutations.

Advanced Non-Small Cell Lung Cancer with HER2 MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Tafasitamab for Pediatric Acute B Lineage Leukemia

We are studying a new treatment for children with relapsed or refractory acute B lineage leukemia to see if it can help delay disease relapse and improve survival rates.

Acute Lymphoblastic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyPediatrics

Hearing Loss in Children: DB-OTO Gene Therapy

We are testing a new gene therapy for children and infants with hearing loss due to specific genetic mutations. The study aims to see if it is safe and effective in improving their hearing and speech skills.

Congenital Hearing Loss1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOtolaryngologyPediatrics

Cobolimab and Dostarlimab for Pediatric Tumors

We are studying a combination of two medications for children and young adults with newly diagnosed or relapsed solid tumors. The goal is to evaluate safety and how well it may work against specific cancers.

Hepatic CancerRhabdomyosarcomaGlioma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyPediatrics

Sasanlimab for Muscle Invasive Bladder Cancer

We are studying whether sasanlimab can help patients with muscle invasive bladder cancer keep their bladder intact after initial treatment. The trial looks at survival rates and quality of life for participants.

Invasive Bladder Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

NRAS Mutant Melanoma: Naporafenib + Trametinib Study

We are testing a new combination therapy for patients with previously treated NRAS mutant cutaneous melanoma. The goal is to see if it works better than standard treatment options in improving survival and managing the disease.

Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesDermatologyOncology

Metastatic Breast Cancer: New HER2 Imaging Test

We are studying a new imaging method using 68Ga-ABS011 to see how well it detects HER2 status in metastatic breast cancer and other solid tumors. This may help improve diagnosis and treatment management.

Metastatic Breast Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineOncology

Hepatocellular Carcinoma: Triple Treatment Study

We are studying a combination of three medications for patients with non-resectable liver cancer. The goal is to see if this approach improves symptoms and quality of life compared to past treatments.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology

Ulcerative Colitis: Filgotinib for Kids and Teens

We are studying the effects of filgotinib in children and teenagers with moderately to severely active ulcerative colitis. The trial aims to see if it helps achieve remission and improves quality of life.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

HYSTINDO Study: Indocyanine Green in Laparoscopic Hysterectomy

We are exploring how a special dye can help surgeons see blood flow in the vaginal area during laparoscopic hysterectomy. This study aims to improve surgical safety and outcomes for patients.

Total Hysterectomy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInternal Medicine

Crohn's Disease in Children: Mirikizumab Study

We are studying whether Mirikizumab can help children with moderately to severely active Crohn's Disease achieve better health compared to a placebo. This research aims to improve treatment options for young patients.

Crohn's Disease1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Fanconi Anemia: Afatinib for Advanced Squamous Cell Carcinoma

We are studying whether Afatinib can help patients with Fanconi anemia who have advanced squamous cell carcinoma in the head and neck. The trial will assess its effectiveness and safety compared to current treatment options.

Advanced Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

dTap Booster Vaccination for Health Care Workers

We are studying the immune response of health care workers to a dTap booster vaccine for pertussis, diphtheria, and tetanus. This helps us understand how well the vaccine boosts their immunity.

Diphtheria, Tetanus, and Pertussis Immunization1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Chronic Myeloid Leukemia: Olverembatinib Study

We are testing a new drug, Olverembatinib, for patients with Chronic Phase Chronic Myeloid Leukemia. The study aims to see if it works better than the current treatment, Bosutinib, especially for those with a specific mutation.

Chronic Myeloid Leukemia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Breast Cancer: Alisertib with Hormone Therapy

We are studying how well alisertib works with hormone therapy for patients with recurrent or metastatic hormone receptor positive, HER2 negative breast cancer. Our goal is to find the best dose and assess safety and effectiveness.

Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology